Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This ain't a large cap stock. Don't even have earnings yet, yet you expect it to have Phizer's numbers. please
We've been in an overall uptrend, along w/the market, for months dude. Look at a 3-6 mo chart. Hit a 4 mo closing high today and 3 mo high for vol
Precision medicine significantly increases chances for new drug approval, by about 40% on average. Although most anavex critics ignore it, don't consider it, and pooh pooh it. Anavex didn't delay their trials for an entire year and spend $ on it for nothing. It is the big thing in 21st century medicine, tho nary a peep about it here, unless I bring it up. I wonder why?
Oh, so 2-73 isn't in competition w/donepezil, or the 3 other alzheimers drugs, for fda approval? 2-73 may also have fewer side effects than those other drugs. Donepezil has anticholinergic side effects, for ex.
Are the 4 approved ad drugs also fda approved for pdd and rett?
Should the results of this P2 pdd trial be viewed thru the lens of precision medicine? considering anavex delayed their trials by over an entire year to address precision medicine and then incorporate it into the assessment and interpretation of their trials, of course the upcoming pdd trial results should be interpreted thru the lens of precision medicine! however, anavex's critics will purposefully not do this! investors should be mindful of that in the future
Does missling have access to ole acquired data, or is that blinded from him?
'Open Label Extension, or OLE, may begin after the randomized (blinded) portion of the trial is completed and if one or both drugs are found to have the potential for benefit. Eligible trial participants will take the active form of the drug without placebo.' - definition from Washington School of Medicine.
Using that logic, then the 4 fda approved drugs for alzheimers also should be immediately approved for rett and pdd. If they work for one it's assumed they work for the others too, no?
Uptrend since mid March. Royally outpacing the market.
corinne lasmezas is still on the anavex scientific advisory board. top expert on prions and mad cow. insert-text-here
unlike previous cns trials, avxl is using precision medicine. keep that in mind when assessing future trial results. avxl critics, competition, and shorts will not consider this, to be sure
If Aricept is the SOC (standard of care) for treating alzheimer's, how then did the 3 other drugs prescribed for alzheimer's obtain fda approval? They were approved years after Aricept was approved back in 1996.
your expectations are set way too high and unrealistic. slowing decline in a percentage of patients is what is more realistically hoped for, and even that would be very impressive and major news
What results expected on 5/4??
Great opportunity for a short squeeze.
Use tight stops to minimize your losses
margin call
Precision medicine wasn't used to select subjects
Why would it attack the body's own tissue?
Biogen might be waiting to see how 2-73 fares in the other trials first before backing clinical trials
Thought so. So, the overall results for the trials will not be including precision medicine. No doubt the shorts will exploit that if any results are just so-so or underwhelming. Digging deeper into Anavex's trial results should reveal results for those with favorable genes and those without. Those are the results we should remember to most focus on. I'm a little concerned Anavex is using such low doses for the Rett and Parkinson's trials. I know they're concerned about safety and side effects, especially for the Rett trials, but man 5mg seems low.
Has Anavex screened patients using precision medicine criteria before admitting them into the Alzheimers Ph2/3 trial? What I mean is, do enrollees have to possess the more favorable Sigma-1R and COMT genes? Is this true, or not, for the other ongoing Ph2 trials as well?
Does it bother you that Anavex is receiving more exposure at prominent events?
Yes Biochecker,
How is it so many "me too" drugs get approved by FDA if they fail to prove in clinical trials they are significantly better and/or safer or better tolerated than the existed SOC? Examples might be allergy meds. First we had Claritin as the first second gen antihistamine. Then came Allegra, then Zyrtec, then Xyzal. For steroidal nose sprays, first was Flonase, then the other steroidal nose sprays (Rhinocort, Nasocort, Beconase, Dymista, Nasarel, Nasonex, Qnasl, Vancenase, Veramyst, and Zetonna). None, according to my allergist and my own experience is significantly better than the rest. They're all pretty much the same. So what gives?
It's just another way of writing Ph 2/3 imo
2-73 highlighted. Maybe some of those authors will be hired at Anavex's future european headquarters in Germany. Wunderbar!
Do tell Georgie
Good to know DMSB approval is the kiss of death for trials
Prolly not til approval for Parkinson's or Alzheimers. When's that? IDK, 2 years maybe. But could happen sooner if circumstances change, Anavex wants to initiate many more trials, or a BP offers Missling a deal he can't refuse
Harald Hampel is lead author. If he wrote that section, or is in agreement w/it, you'd think he, and by extension Eisai, would be very interested in Anavex's pipeline of sigma-1 drugs.
Gut microbes effect the metabolism and absorption of drugs